Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $7.25.

Several research analysts have recently issued reports on MIST shares. Wells Fargo & Company cut their price target on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Raymond James Financial initiated coverage on Milestone Pharmaceuticals in a research note on Friday, April 10th. They set a “strong-buy” rating and a $6.00 price target for the company. Finally, Zacks Research downgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, May 15th.

Insiders Place Their Bets

In related news, CEO Joseph Oliveto sold 36,500 shares of the business’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the completion of the transaction, the chief executive officer owned 446,244 shares of the company’s stock, valued at approximately $1,008,511.44. The trade was a 7.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.50% of the company’s stock.

Institutional Trading of Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Creative Planning grew its holdings in Milestone Pharmaceuticals by 74.6% in the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after buying an additional 10,000 shares during the period. Raymond James Financial Inc. grew its holdings in shares of Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after purchasing an additional 10,000 shares during the period. Bay Rivers Group grew its holdings in shares of Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after purchasing an additional 12,170 shares during the period. Strategic Family Wealth Counselors L.L.C. purchased a new stake in shares of Milestone Pharmaceuticals during the 4th quarter worth about $25,000. Finally, Eaton Financial Holdings Company LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 4th quarter worth about $26,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Stock Performance

NASDAQ:MIST opened at $1.27 on Friday. The company has a market capitalization of $158.12 million, a PE ratio of -1.87 and a beta of 0.95. The company has a quick ratio of 9.09, a current ratio of 9.18 and a debt-to-equity ratio of 1.61. Milestone Pharmaceuticals has a 52-week low of $1.00 and a 52-week high of $3.06. The stock has a fifty day simple moving average of $1.65 and a 200-day simple moving average of $1.84.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.26). The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $30.12 million. On average, equities research analysts expect that Milestone Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.